Votes & Verdicts

45 - Is TikTok on the Countdown to a Shutdown?

Votes and Verdicts is a series that examines the intersection of business, policy and law. It features conversations between Bloomberg Intelligence's team of litigation and policy analysts and thought leaders discussing legal and policy issues affecting markets and business decisions across many sectors.

Weitere Folgen

45 - Is TikTok on the Countdown to a Shutdown?

Thu, 09 May 2024
44 - Google, LiveNation, Uber and Other Catalysts

Fri, 03 May 2024
43 - Kelleher on FinReg, ‘Kangaroo’ Courts

Thu, 18 Apr 2024
42 - Pharma and Biotech Drug Pricing Policy Outlook

Thu, 11 Apr 2024
41 - Antitrust Enforcers’ New Merger Guidelines

Thu, 21 Mar 2024
40 - Eugene Scalia on Beating Regulators in Court

Tue, 12 Mar 2024
39 - Market and Reimbursement Outlook for Cell and Gene Therapies

Thu, 07 Mar 2024
38 - 3M, Synopsys, Capital One & Other Catalysts

Fri, 01 Mar 2024
37 - Can Legal State Pot Put US Law Up in Smoke?

Tue, 27 Feb 2024
36 - Biden’s Lab-Developed Test Proposal

Tue, 20 Feb 2024
35 - Biden’s Drug-Pricing Expansion Plan, Part 2

Tue, 13 Feb 2024
34 - Apple, Bayer, Moderna and Other Catalysts

Fri, 02 Feb 2024
33 - Apple’s Antitrust App-Store Battle With Epic

Thu, 25 Jan 2024
32 - Washington’s Crowded Outlook for 2024

Tue, 23 Jan 2024
31 - Biden’s Drug Pricing March-in Proposal

Thu, 18 Jan 2024
30 - Meta’s Biggest Legal, Regulatory Questions

Mon, 18 Dec 2023
29 - Antitrust Changes Could Hinder M&A

Mon, 11 Dec 2023
28 - Apple, Disney, Novo Nordisk, Other Catalysts

Fri, 01 Dec 2023
27 - J&J, 3M's Chap 11 Play in Talc, Earplug Mass Torts

Tue, 14 Nov 2023
26 - Berkshire, Google, Pega & Other Catalysts

Fri, 03 Nov 2023
25 - Consumer Finance Impact of a CFPB Run Amok

Tue, 31 Oct 2023
24 - Will IRA Drug Pricing Raise Employer Costs?

Tue, 17 Oct 2023
23 - JJCI, Bayer, GSK, Mass Tort Litigation Risks

Mon, 09 Oct 2023
22 - Bausch, GBTC, Merck, Meta & Other Catalysts

Fri, 29 Sep 2023
21 - AI’s Biggest Legal and Regulatory Questions

Tue, 26 Sep 2023
20 - FTC BioPharma M&A Approach Clashes With Sector

Thu, 21 Sep 2023
19 - Likelihood Medicare Will Cover Obesity Drugs

Tue, 05 Sep 2023
18 - 3M, Drug Pricing, Google and Other Catalysts

Wed, 30 Aug 2023
17 - Can Anyone Defeat Trump? Insights on the Forthcoming GOP Debates

Thu, 17 Aug 2023
16 - 3M, Google, Bank Rules, Other 2H Catalysts

Fri, 21 Jul 2023
15 - Craig Burton on Inflation Reduction Act

Wed, 19 Jul 2023
14 - Why PFAS Legal Risks Persist for 3M, Peers

Thu, 13 Jul 2023
13 - Why a TikTok Ban Faces a Major Legal Hurdle

Tue, 06 Jun 2023
12 - Catalysts to Watch – AI Laws, PFAS Trial

Fri, 02 Jun 2023
11 - Adamantine’s Bays on Sustainable Investing

Wed, 31 May 2023
10 - Margaux Hall on Drug Pricing Negotiation

Wed, 24 May 2023
9 - Bill Hoagland on Debt-Ceiling Negotiations

Mon, 15 May 2023
8 - Daniel Horwitz on Trump Indictment Strengths

Mon, 15 May 2023
7 - Gottlieb on the Future of Crypto Policy, Law

Mon, 15 May 2023
6 - The PFAS Problem, Regulatory and Other Issues

Mon, 15 May 2023
5 - Crisis of Confidence, Regional Banks’ Future

Mon, 15 May 2023
4 - The FTC’s Evolving Approach to Assessing M&A

Mon, 15 May 2023
3 - The Biggest Tech-Regulation Questions

Mon, 15 May 2023
2 - Energy's DC Opportunity, Risk with Schneider

Mon, 15 May 2023
1 - Mulvaney on Crypto, the CFPB, and More

Tue, 09 May 2023

Weitere Folgen anzeigen

Weitere geschäft-Podcasts

Weitere internationale geschäft-Podcasts

Finden Sie Ihr Radio